



8 May 2020

Sydney, Australia

Appointment of New Board Member

Sydney, 8 May 2020: Noxopharm (ASX:NOX) is pleased to announce the appointment of Mr Fred Bart as a Non-Executive Director to the Company's Board.

Mr Bart is an additional appointment to the Board under the casual vacancy provisions of the Constitution.

Fred Bart has been Chairman and Managing Director of numerous private and public companies since 1980, specialising in manufacturing, technology, property and marketable securities. Fred Bart is Chairman of ASX listed companies, Electro Optic Systems Holdings Limited and Audio Pixels Holdings Limited and is a director of Weebit Nano Limited. Mr Bart also is a director of Immunovative Therapies Limited, an Israeli company involved in the manufacture of cancer vaccines for the treatment of most forms of cancer.

Graham Kelly, Noxopharm CEO and Executive Chairman, said, "Fred joins the Company at an important time in its life as it moves from early-stage clinical trials to a commercial and partnering phase. Fred brings strong business acumen and experience in equity markets, complementing Board skills that have brought the Company to its current strong position."

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda[®] and is the major shareholder in U.S. biotechnology company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Media enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111



E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.